Literature DB >> 9709469

Study size and documentation to detect injection-related hepatitis C in prison.

S M Gore1, A G Bird.   

Abstract

We used existing data on hepatitis C prevalence, injection-related hepatitis C transmission and needle use in prisons and new data on infectiousness, to estimate the size of study required to detect injection-related hepatitis C in UK prisons. A pilot study of 500 prisoners followed for 10 weeks would have a 65% chance of detecting a hepatitis C seroconversion, conservatively assuming one injection per prisoner per week, and a 3% transmission rate per injection, but uncertainty might persist as to whether transmission had occurred during a short incarceration or before it. If the actual transmission rate was 10%, as recently documented, then such a study would have more adequate statistical power. A definitive study of 3000 prisoners for 10 weeks would expect to detect about six seroconversions, even with conservative estimates of injection frequency and transmission rate. Adequate design and power of these studies is important because of the complacency that could result from false-negative findings. We suggest six risk-factor themes that studies should document.

Entities:  

Mesh:

Year:  1998        PMID: 9709469     DOI: 10.1093/qjmed/91.5.353

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  5 in total

1.  Modeling the initiation of others into injection drug use, using data from 2,500 injectors surveyed in Scotland during 2008-2009.

Authors:  Simon R White; Sharon J Hutchinson; Avril Taylor; Sheila M Bird
Journal:  Am J Epidemiol       Date:  2015-03-18       Impact factor: 4.897

2.  A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada.

Authors:  Ehsan Jozaghi; Andrew A Reid; Martin A Andresen
Journal:  Subst Abuse Treat Prev Policy       Date:  2013-07-09

3.  Impact of opioid substitution therapy for Scotland's prisoners on drug-related deaths soon after prisoner release.

Authors:  Sheila M Bird; Colin M Fischbacher; Lesley Graham; Andrew Fraser
Journal:  Addiction       Date:  2015-06-08       Impact factor: 6.526

4.  Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial.

Authors:  John Strang; Sheila M Bird; Mahesh K B Parmar
Journal:  J Urban Health       Date:  2013-10       Impact factor: 3.671

5.  A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada.

Authors:  Ehsan Jozaghi; Andrew A Reid; Martin A Andresen; Alexandre Juneau
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.